In vitro interactions of approved and novel drugs against Paecilomyces spp

Montserrat Ortoneda1, Javier Capilla, F Javier Pastor

  • 1Unitat de Microbiologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, Carrer Sant Llorenç, 21.43201 Reus, Spain.

Insights

This study explored antifungal drug combinations against Paecilomyces species. Terbinafine showed synergistic effects with azoles, while amphotericin B and micafungin interactions were mostly indifferent.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Paecilomyces species are emerging fungal pathogens.
  • Effective antifungal treatments are crucial for managing Paecilomyces infections.

Purpose of the Study:

  • To evaluate the in vitro activity of various antifungal drug combinations against Paecilomyces variotii and Paecilomyces lilacinus.
  • To identify synergistic or indifferent interactions between different antifungal agents.

Main Methods:

  • In vitro testing of 15 drug combinations.
  • Antifungal drugs included amphotericin B, azoles (itraconazole, voriconazole, albaconazole, ravuconazole), terbinafine, and micafungin.
  • Tested against four Paecilomyces variotii and three Paecilomyces lilacinus isolates.

Main Results:

  • Terbinafine demonstrated synergistic interactions with 53% of the tested azole combinations.
  • Amphotericin B and micafungin showed mainly indifferent interactions with other antifungal agents.
  • Varied responses were observed across different drug combinations and Paecilomyces species.

Conclusions:

  • Terbinafine combined with azoles presents a promising strategy for treating Paecilomyces infections.
  • Amphotericin B and micafungin may have limited synergistic potential when combined with other antifungals in this context.
  • Further in vivo studies are warranted to confirm these in vitro findings.

Related Concept Videos